- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.05. | Aardvark Therapeutics strukturiert Führungsteam während Phase-3-Studie um | 2 | Investing.com Deutsch | ||
| 19.05. | Aardvark Therapeutics reshuffles leadership amid Phase 3 study | 2 | Investing.com | ||
| AARDVARK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 19.05. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions | 96 | GlobeNewswire (Europe) | Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian... ► Artikel lesen | |
| 15.05. | Aardvark Therapeutics reports Q1 results | 2 | Seeking Alpha | ||
| 14.05. | Aardvark Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 14.05. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights | 95 | GlobeNewswire (Europe) | Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early 2026$151.3 million in cash, cash equivalents, and short-term... ► Artikel lesen | |
| 01.04. | RBC Capital maintains $21 target on Aardvark Therapeutics stock | 1 | Investing.com | ||
| 01.04. | Cantor Fitzgerald maintains $50 target on Aardvark Therapeutics stock | 1 | Investing.com | ||
| 31.03. | Aardvark Therapeutics, Inc. - 10-K, Annual Report | 4 | SEC Filings | ||
| 31.03. | Aardvark Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.03. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights | 69 | GlobeNewswire (Europe) | Lead candidate ARD-101 demonstrated clinical activity and was generally well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome (PWS), with meaningful reductions in hyperphagia (up to... ► Artikel lesen | |
| 27.03. | BofA lifts Aardvark Therapeutics target to $26, maintains Buy | 2 | Investing.com | ||
| 10.03. | RBC Capital sets Aardvark Therapeutics at Outperform | 1 | Investing.com | ||
| 10.03. | BofA sets Aardvark Therapeutics stock with $22 target | 3 | Investing.com | ||
| 14.02. | Aardvark Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.02. | Aardvark Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 13.02. | Aardvark Therapeutics' Pursuit of New Obesity Target Adds $94M in IPO Cash | 2 | MedCity News | ||
| 13.02. | Aardvark Therapeutics prices $94.2m IPO to fund development of Prader-Willi syndrome drug | 1 | Pharmaceutical Technology | ||
| 13.02. | Metabolic disease biotech Aardvark Therapeutics prices IPO at $16, the low end of the range | 2 | Renaissance Capital | ||
| 13.02. | Aardvark Therapeutics heads to Nasdaq with $94M IPO to fund more appetite-suppressant trials | 2 | FierceBiotech |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,230 | +2,74 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| VOR BIOPHARMA | 0,890 | 0,00 % | Pre-market Movers: Vor Biopharma, Worthington Steel, Surf Air Mobility, Nano Labs, Protagenic Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).In the Green Vor Biopharma Inc. (VOR) is up over 109% at $1.16.
Worthington... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 40,330 | +0,40 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,990 | +0,04 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors | - If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors -
- Decision from European Commission expected in the third... ► Artikel lesen | |
| VERVE THERAPEUTICS | 11,255 | 0,00 % | BMO Capital stuft Verve Therapeutics nach Eli Lilly-Übernahme herab | ||
| EVOTEC | 7,196 | +0,50 % | Evotec-Aktie: Kurs legt zu (6,734 €) | Am deutschen Aktienmarkt notiert die Evotec-Aktie derzeit etwas fester. Zuletzt zahlten Investoren für das Wertpapier 6,73 Euro. Der Anteilsschein von Evotec verzeichnet gegenwärtig einen Preisanstieg... ► Artikel lesen | |
| BIONTECH | 90,80 | +0,17 % | BioNTech schluckt CureVac! Evotec und Vidac als nächstes? Kurstreiber Übernahme und Kaufempfehlung | Steht bei Vidac Pharma eine neue Kursexplosion bevor? Im vergangenen Herbst ging es um rund 200 % nach oben. Gestern gab es eine Kaufempfehlung. Die Analysten sehen bei der Biotech-Perle Vervielfachungspotenzial.... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,410 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,380 | +4,43 % | ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? | ||
| KYMERA THERAPEUTICS | 45,720 | 0,00 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| ITEOS THERAPEUTICS | 10,020 | -0,20 % | iTeos Therapeutics Inc.: iTeos Therapeutics Announces Its Intention to Wind Down Operations | - Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984, EOS-215... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 9,550 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| KEROS THERAPEUTICS | 13,510 | -1,31 % | Keros Therapeutics, Inc.: Keros Announces Return of $375 Million in Excess Capital to Stockholders | LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 13,050 | 0,00 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,310 | 0,00 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |
AARDVARK THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 13,925 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AARDVARK THERAPEUTICS INC finden Sie auf Wallstreet Online.